Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
- Hayden, P. J.
- Roddie, C.
- Bader, P.
- Basak, G. W.
- Bonig, H.
- Bonini, C.
- Chabannon, C.
- Ciceri, F.
- Corbacioglu, S.
- Ellard, R.
- Sanchez-Guijo, F.
- Jäger, U.
- Hildebrandt, M.
- Hudecek, M.
- Kersten, M. J.
- Köhl, U.
- Kuball, J.
- Mielke, S.
- Mohty, M.
- Murray, J.
- Nagler, A.
- Rees, J.
- Rioufol, C.
- Saccardi, R.
- Snowden, J. A.
- Styczynski, J.
- Subklewe, M.
- Thieblemont, C.
- Topp, M.
- Ispizua, U.
- Chen, D.
- Vrhovac, R.
- Gribben, J. G.
- Kröger, N.
- Einsele, H.
- Yakoub-Agha, I.
DOIAbstract
Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. Design: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality ca...
Add to ORKG